University of Pennsylvania researchers share evidence-based strategies for reducing unplanned emergency department and hospitalizations of patients with cancer.
Non Hodgkin Lymphoma
A study evaluated how treating military veterans with HCV early impacted their risk for non-Hodgkin lymphoma and various other diseases.
Can you identify the latest developments related to the treatment of blood cancers? Test your knowledge.
Analysis from Avalere shows why healthcare execs should understand how oncology practices are evolving in response to the OCM.
In a decision reached through the joint FDA/CMS Parallel Review process, CMS has granted national Medicare coverage to next-generation sequencing tests approved or cleared by the FDA as companion diagnostics for cancer therapies. This is clearly a win for Medicare beneficiaries and some NGS test providers—but is it also good news for MCOs?
Two experts highlight noteworthy updates in the transplant and cellular therapy space. Read more.
The Center for Blood and Cancer Disorders in Fort Worth, Texas, is participating in many value-based contracts. Here’s how it is successful.
New treatment approaches could lead to even higher costs associated with lymphoma. However, experts say these treatments hold great promise and could reduce costs in the long-term.
Unique trends are occurring in the pharmaceutical pipeline that would have been unheard of just five years ago.
Technology professionals shed light on the “Wearable Revolution,” what’s new in wearables, and what the future holds.